Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo)
Antibody fragment
Evidence outlook
Approved: Generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Competitive landscape
Other FcRn drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Inflammatory Demyelinating Polyneuropathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo): this drug | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Efgartigimod Alfa (Vyvgart) | Approved(overall) | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Riliprubart | Phase 3 | Monoclonal antibody | Complement C1s | not yet graded | No reviewed efficacy summary in this indication | |
| Imeroprubart | Phase 2 | Monoclonal antibody | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-411 | —(overall) | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.